Frimley Park Hospital, Camberley, Surrey, Royal Surrey County Hospital, Guildford, Surrey, UK.
Study Type - Diagnostic (exploratory cohort) Level of Evidence 3b.
What's known on the subject? and What does the study add? The optimal method of active surveillance in prostate cancer remains unknown. This study is one of the first to report on the role of transperineal template prostate biopsies in active surveillance. It demonstrates that around one third of men are reclassified with more significant prostate cancer at an early stage in their management. This is a higher proportion than reported in contemporary cancers using standard transrectal biopsies for restaging.
To evaluate the role of transperineal template prostate biopsies in men on active surveillance.
In all, 101 men on active surveillance for prostate cancer underwent restaging transperineal template prostate biopsies at a single centre. Criteria for active surveillance were ≤ 75 years, Gleason ≤ 3+3, prostate-specific antigen (PSA) ≤ 15 ng/mL, clinical stage T1-2a and ≤ 50% ultrasound-guided transrectal biopsy cores positive for cancer with ≤ 10 mm of disease in a single core. The number of men with an increase in disease volume or Gleason grade on transperineal template biopsy and the number of men who later underwent radical treatment were assessed. The role of PSA and PSA kinetics were studied.
In all, 34% of men had more significant prostate cancer on restaging transperineal template biopsies compared with their transrectal biopsies. Of these men, 44% had disease predominantly in the anterior part of the gland, an area often under-sampled by transrectal biopsies. In the group of men who had their restaging transperineal template biopsies within 6 months of commencing active surveillance 38% had more significant disease. There was no correlation with PSA velocity or PSA doubling time. In total, 33% of men stopped active surveillance and had radical treatment.
Around one-third of men had more significant prostate cancer on transperineal template biopsies. This probably reflects under-sampling by initial transrectal biopsies rather than disease progression.
Written by:
Ayres BE, Montgomery BS, Barber NJ, Pereira N, Langley SE, Denham P, Bott SR. Are you the author?
Reference: BJU Int. 2011 Aug 19. Epub ahead of print.
doi: 10.1111/j.1464-410X.2011.10480.x
PubMed Abstract
PMID: 21854535
UroToday.com Prostate Cancer Section
